https://www.selleckchem.com/pr....oducts/ac-devd-cho.h
The GMFI varied from 4.3 - 22.7 in the test and 3.7-21.6 in the reference vaccine group. The seroprotection rates were 90% for the A-strains and ranged between 43% and less then 60% for B-strains for both the vaccines. Seroconversion rates varied between 41.4% and 78.8%. Overall, the reported adverse events (AEs) for both the vaccines were less then 1% and comparable. Reported local and systemic reactions were comparable.Conclusion Influvac® Tetra elicited an adequate immune response with a favorable safety profile which was